Calidi's FY2023 loss widens to $29.2M; cash only $1.9M; capital raise needed for key trials

Calidi Biotherapeutics, Inc.

Net loss for FY2023 was $29.2M ($1.73 per share) vs $25.4M ($2.99 per share) in FY2022.
Cash and restricted cash totaled $2.1M at Dec 31, 2023, up from $0.6M a year prior but still low.
Q4 R&D expenses rose to $4.0M (from $2.3M) and G&A to $5.9M (from $2.4M) year-over-year.
City of Hope received $5.3M CIRM grant for CLD-101 ovarian cancer study; RTNova platform announced.
Interim Phase 1 data for CLD-101 expected 2Q 2024 'assuming we are successful in raising additional capital.'

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Calidi Biotherapeutics, Inc. reported financial results for fourth quarter and full fiscal year ended December 31, 2023.

Period: fourth quarter and full fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 15, 2024, Calidi Biotherapeutics, Inc. (the "Company") issued a press release setting forth certain financial and operational information for its fourth fiscal quarter and full fiscal year ended December 31, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Calidi Biotherapeutics, Inc. reported three months ended December 31, 2023 results: net income net loss of $8.2 million, or $0.23 per share, EPS $0.23 per share.

Period: three months ended December 31, 2023
Net income: net loss of $8.2 million, or $0.23 per share
EPS: $0.23 per share
Result: reported results

Exact text from the filing

The company reported a net loss of $8.2 million, or $0.23 per share, for the three months ended December 31, 2023, compared to a net loss of $7.8 million, or $0.90 per share, for the same period in 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Calidi Biotherapeutics, Inc. reported year ended December 31, 2023 results: net income net loss of $29.2 million, or $1.73 per share, EPS $1.73 per share.

Period: year ended December 31, 2023
Net income: net loss of $29.2 million, or $1.73 per share
EPS: $1.73 per share
Result: reported results

Exact text from the filing

The company reported a net loss of $29.2 million, or $1.73 per share, for the year ended December 31, 2023, compared to a net loss of $25.4 million, or $2.99 per share, for the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-010208

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.